nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Topoisomerase Inhibitors—Irinotecan—colon cancer	0.474	1	CiPCiCtD
Epirubicin—liver cancer—colon cancer	0.0907	0.254	CtDrD
Epirubicin—breast cancer—colon cancer	0.0766	0.215	CtDrD
Epirubicin—stomach cancer—colon cancer	0.066	0.185	CtDrD
Epirubicin—ovarian cancer—colon cancer	0.0616	0.173	CtDrD
Epirubicin—pancreatic cancer—colon cancer	0.0616	0.173	CtDrD
Epirubicin—ABCC1—Irinotecan—colon cancer	0.0277	0.416	CbGbCtD
Epirubicin—ABCC1—Vincristine—colon cancer	0.0242	0.364	CbGbCtD
Epirubicin—ABCC1—Methotrexate—colon cancer	0.0147	0.22	CbGbCtD
Epirubicin—CHD1—Topotecan—Irinotecan—colon cancer	0.00089	0.541	CbGdCrCtD
Epirubicin—CHD1—lymphoid tissue—colon cancer	0.000767	0.0441	CbGeAlD
Epirubicin—AURKA—renal system—colon cancer	0.000744	0.0428	CbGeAlD
Epirubicin—CHD1—bone marrow—colon cancer	0.000698	0.0402	CbGeAlD
Epirubicin—CHD1—vagina—colon cancer	0.000669	0.0385	CbGeAlD
Epirubicin—AURKA—lymphoid tissue—colon cancer	0.000618	0.0356	CbGeAlD
Epirubicin—AURKA—digestive system—colon cancer	0.00061	0.0351	CbGeAlD
Epirubicin—YWHAG—smooth muscle tissue—colon cancer	0.000593	0.0341	CbGeAlD
Epirubicin—YWHAG—renal system—colon cancer	0.000571	0.0329	CbGeAlD
Epirubicin—CHD1—liver—colon cancer	0.000564	0.0325	CbGeAlD
Epirubicin—AURKA—bone marrow—colon cancer	0.000563	0.0324	CbGeAlD
Epirubicin—AURKA—vagina—colon cancer	0.000539	0.031	CbGeAlD
Epirubicin—DHCR7—lymphoid tissue—colon cancer	0.000517	0.0297	CbGeAlD
Epirubicin—UGT2B7—renal system—colon cancer	0.000516	0.0297	CbGeAlD
Epirubicin—DHCR7—digestive system—colon cancer	0.000511	0.0294	CbGeAlD
Epirubicin—YWHAG—lymphoid tissue—colon cancer	0.000474	0.0273	CbGeAlD
Epirubicin—DHCR7—bone marrow—colon cancer	0.000471	0.0271	CbGeAlD
Epirubicin—YWHAG—digestive system—colon cancer	0.000469	0.027	CbGeAlD
Epirubicin—AURKA—liver—colon cancer	0.000455	0.0262	CbGeAlD
Epirubicin—DHCR7—vagina—colon cancer	0.000451	0.0259	CbGeAlD
Epirubicin—PLA2G4A—smooth muscle tissue—colon cancer	0.000443	0.0255	CbGeAlD
Epirubicin—CHD1—lymph node—colon cancer	0.000433	0.0249	CbGeAlD
Epirubicin—YWHAG—bone marrow—colon cancer	0.000432	0.0249	CbGeAlD
Epirubicin—PLA2G4A—renal system—colon cancer	0.000426	0.0245	CbGeAlD
Epirubicin—UGT2B7—digestive system—colon cancer	0.000423	0.0243	CbGeAlD
Epirubicin—YWHAG—vagina—colon cancer	0.000414	0.0238	CbGeAlD
Epirubicin—DHCR7—liver—colon cancer	0.00038	0.0219	CbGeAlD
Epirubicin—YWHAG—liver—colon cancer	0.000349	0.0201	CbGeAlD
Epirubicin—AURKA—lymph node—colon cancer	0.000349	0.0201	CbGeAlD
Epirubicin—PLA2G4A—bone marrow—colon cancer	0.000322	0.0185	CbGeAlD
Epirubicin—UGT2B7—liver—colon cancer	0.000315	0.0181	CbGeAlD
Epirubicin—PLA2G4A—vagina—colon cancer	0.000309	0.0178	CbGeAlD
Epirubicin—TOP2A—bone marrow—colon cancer	0.000306	0.0176	CbGeAlD
Epirubicin—TOP2A—vagina—colon cancer	0.000293	0.0169	CbGeAlD
Epirubicin—AURKA—Topotecan—Irinotecan—colon cancer	0.000293	0.178	CbGdCrCtD
Epirubicin—DHCR7—lymph node—colon cancer	0.000292	0.0168	CbGeAlD
Epirubicin—YWHAG—lymph node—colon cancer	0.000268	0.0154	CbGeAlD
Epirubicin—PLA2G4A—lymph node—colon cancer	0.0002	0.0115	CbGeAlD
Epirubicin—TOP2A—lymph node—colon cancer	0.00019	0.0109	CbGeAlD
Epirubicin—PLA2G4A—Raltitrexed—Methotrexate—colon cancer	0.000186	0.113	CbGdCrCtD
Epirubicin—ABCC1—vagina—colon cancer	0.000177	0.0102	CbGeAlD
Epirubicin—ABCC1—liver—colon cancer	0.000149	0.00857	CbGeAlD
Epirubicin—ABCC1—lymph node—colon cancer	0.000114	0.00657	CbGeAlD
Epirubicin—TOP2A—Topotecan—Irinotecan—colon cancer	0.000112	0.068	CbGdCrCtD
Epirubicin—Daunorubicin—ABCB1—colon cancer	0.000105	0.552	CrCbGaD
Epirubicin—Doxorubicin—ABCB1—colon cancer	8.5e-05	0.448	CrCbGaD
Epirubicin—TOP2A—Vindesine—Vincristine—colon cancer	8e-05	0.0486	CbGdCrCtD
Epirubicin—PLA2G4A—PDGF Pathway—HRAS—colon cancer	5.05e-05	0.00209	CbGpPWpGaD
Epirubicin—TOP2A—Vinorelbine—Vincristine—colon cancer	5.05e-05	0.0307	CbGdCrCtD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—SRC—colon cancer	5e-05	0.00207	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	4.96e-05	0.00206	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—TYMS—colon cancer	4.95e-05	0.00205	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TGFB1—colon cancer	4.9e-05	0.00203	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—MLH1—colon cancer	4.89e-05	0.00203	CbGpPWpGaD
Epirubicin—PLA2G4A—Endothelins—SRC—colon cancer	4.89e-05	0.00203	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	4.87e-05	0.00202	CbGpPWpGaD
Epirubicin—YWHAG—mTOR signaling pathway—AKT1—colon cancer	4.83e-05	0.002	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—MYC—colon cancer	4.74e-05	0.00196	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	4.71e-05	0.00195	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—SRC—colon cancer	4.71e-05	0.00195	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—TYMS—colon cancer	4.71e-05	0.00195	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—EGFR—colon cancer	4.7e-05	0.00195	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—SRC—colon cancer	4.66e-05	0.00193	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—BUB1B—colon cancer	4.65e-05	0.00193	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—EGFR—colon cancer	4.63e-05	0.00192	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	4.54e-05	0.00188	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—CASP3—colon cancer	4.5e-05	0.00187	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—NRAS—colon cancer	4.48e-05	0.00186	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—CASP3—colon cancer	4.48e-05	0.00186	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	4.46e-05	0.00185	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—KRAS—colon cancer	4.44e-05	0.00184	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—EGFR—colon cancer	4.38e-05	0.00182	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—KRAS—colon cancer	4.38e-05	0.00182	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—CTNNB1—colon cancer	4.34e-05	0.0018	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—BRAF—colon cancer	4.32e-05	0.00179	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—CTNNB1—colon cancer	4.32e-05	0.00179	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	4.3e-05	0.00178	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CA7—colon cancer	4.22e-05	0.00175	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—TYMS—colon cancer	4.21e-05	0.00174	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—MYC—colon cancer	4.18e-05	0.00173	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—BUB1B—colon cancer	4.16e-05	0.00172	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—KRAS—colon cancer	4.14e-05	0.00172	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—EGFR—colon cancer	4.13e-05	0.00171	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—PIK3CA—colon cancer	4.08e-05	0.00169	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—colon cancer	4.04e-05	0.00167	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—EP300—colon cancer	4.01e-05	0.00166	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—colon cancer	3.9e-05	0.00162	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.9e-05	0.00162	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—TP53—colon cancer	3.89e-05	0.00161	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—KRAS—colon cancer	3.86e-05	0.0016	CbGpPWpGaD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—PIK3CA—colon cancer	3.81e-05	0.00158	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—VEGFA—colon cancer	3.8e-05	0.00158	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—APC—colon cancer	3.78e-05	0.00157	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—HRAS—colon cancer	3.77e-05	0.00156	CbGpPWpGaD
Epirubicin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—colon cancer	3.73e-05	0.00155	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—TYMS—colon cancer	3.57e-05	0.00148	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—PIK3CA—colon cancer	3.55e-05	0.00147	CbGpPWpGaD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—colon cancer	3.53e-05	0.00146	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—HRAS—colon cancer	3.52e-05	0.00146	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—PPARG—colon cancer	3.5e-05	0.00145	CbGpPWpGaD
Epirubicin—TOP2A—Vinblastine—Vincristine—colon cancer	3.47e-05	0.0211	CbGdCrCtD
Epirubicin—PLA2G4A—Endothelins—HRAS—colon cancer	3.44e-05	0.00143	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—CCND1—colon cancer	3.42e-05	0.00142	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MLH1—colon cancer	3.42e-05	0.00142	CbGpPWpGaD
Epirubicin—Oedema—Fluorouracil—colon cancer	3.41e-05	0.000573	CcSEcCtD
Epirubicin—Anaphylactic shock—Fluorouracil—colon cancer	3.41e-05	0.000573	CcSEcCtD
Epirubicin—Anorexia—Irinotecan—colon cancer	3.39e-05	0.00057	CcSEcCtD
Epirubicin—Ataxia—Methotrexate—colon cancer	3.39e-05	0.00057	CcSEcCtD
Epirubicin—Infection—Fluorouracil—colon cancer	3.39e-05	0.000569	CcSEcCtD
Epirubicin—Haemoglobin—Capecitabine—colon cancer	3.37e-05	0.000567	CcSEcCtD
Epirubicin—Rhinitis—Capecitabine—colon cancer	3.36e-05	0.000565	CcSEcCtD
Epirubicin—Hepatitis—Capecitabine—colon cancer	3.35e-05	0.000564	CcSEcCtD
Epirubicin—Haemorrhage—Capecitabine—colon cancer	3.35e-05	0.000564	CcSEcCtD
Epirubicin—Nervous system disorder—Fluorouracil—colon cancer	3.34e-05	0.000562	CcSEcCtD
Epirubicin—Thrombocytopenia—Fluorouracil—colon cancer	3.34e-05	0.000561	CcSEcCtD
Epirubicin—Hypoaesthesia—Capecitabine—colon cancer	3.34e-05	0.000561	CcSEcCtD
Epirubicin—YWHAG—Membrane Trafficking—SRC—colon cancer	3.33e-05	0.00138	CbGpPWpGaD
Epirubicin—Liver function test abnormal—Methotrexate—colon cancer	3.33e-05	0.00056	CcSEcCtD
Epirubicin—YWHAG—ErbB1 downstream signaling—AKT1—colon cancer	3.33e-05	0.00138	CbGpPWpGaD
Epirubicin—Musculoskeletal discomfort—Vincristine—colon cancer	3.33e-05	0.00056	CcSEcCtD
Epirubicin—Pharyngitis—Capecitabine—colon cancer	3.33e-05	0.00056	CcSEcCtD
Epirubicin—Tachycardia—Fluorouracil—colon cancer	3.33e-05	0.000559	CcSEcCtD
Epirubicin—Hypotension—Irinotecan—colon cancer	3.33e-05	0.000559	CcSEcCtD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—colon cancer	3.31e-05	0.00137	CbGpPWpGaD
Epirubicin—Urinary tract disorder—Capecitabine—colon cancer	3.31e-05	0.000557	CcSEcCtD
Epirubicin—Insomnia—Vincristine—colon cancer	3.3e-05	0.000556	CcSEcCtD
Epirubicin—Oedema peripheral—Capecitabine—colon cancer	3.3e-05	0.000555	CcSEcCtD
Epirubicin—Connective tissue disorder—Capecitabine—colon cancer	3.29e-05	0.000554	CcSEcCtD
Epirubicin—Urethral disorder—Capecitabine—colon cancer	3.29e-05	0.000553	CcSEcCtD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—AKT1—colon cancer	3.29e-05	0.00136	CbGpPWpGaD
Epirubicin—Paraesthesia—Vincristine—colon cancer	3.28e-05	0.000552	CcSEcCtD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—HRAS—colon cancer	3.28e-05	0.00136	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—APC—colon cancer	3.28e-05	0.00136	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ODC1—colon cancer	3.26e-05	0.00135	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CHST5—colon cancer	3.26e-05	0.00135	CbGpPWpGaD
Epirubicin—Breast disorder—Methotrexate—colon cancer	3.26e-05	0.000548	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—BUB1B—colon cancer	3.25e-05	0.00135	CbGpPWpGaD
Epirubicin—Anorexia—Fluorouracil—colon cancer	3.25e-05	0.000546	CcSEcCtD
Epirubicin—Toxic epidermal necrolysis—Methotrexate—colon cancer	3.25e-05	0.000546	CcSEcCtD
Epirubicin—Visual impairment—Capecitabine—colon cancer	3.23e-05	0.000543	CcSEcCtD
Epirubicin—Insomnia—Irinotecan—colon cancer	3.22e-05	0.000541	CcSEcCtD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—colon cancer	3.21e-05	0.00133	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CHST5—colon cancer	3.2e-05	0.00133	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ODC1—colon cancer	3.2e-05	0.00133	CbGpPWpGaD
Epirubicin—Paraesthesia—Irinotecan—colon cancer	3.2e-05	0.000537	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—TYMS—colon cancer	3.19e-05	0.00132	CbGpPWpGaD
Epirubicin—Hypotension—Fluorouracil—colon cancer	3.18e-05	0.000536	CcSEcCtD
Epirubicin—Decreased appetite—Vincristine—colon cancer	3.18e-05	0.000534	CcSEcCtD
Epirubicin—Dyspnoea—Irinotecan—colon cancer	3.17e-05	0.000534	CcSEcCtD
Epirubicin—Erythema multiforme—Capecitabine—colon cancer	3.17e-05	0.000533	CcSEcCtD
Epirubicin—Somnolence—Irinotecan—colon cancer	3.16e-05	0.000532	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Vincristine—colon cancer	3.15e-05	0.000531	CcSEcCtD
Epirubicin—Fatigue—Vincristine—colon cancer	3.15e-05	0.00053	CcSEcCtD
Epirubicin—Eye disorder—Capecitabine—colon cancer	3.13e-05	0.000527	CcSEcCtD
Epirubicin—Dyspepsia—Irinotecan—colon cancer	3.13e-05	0.000527	CcSEcCtD
Epirubicin—Tinnitus—Capecitabine—colon cancer	3.13e-05	0.000526	CcSEcCtD
Epirubicin—Pain—Vincristine—colon cancer	3.12e-05	0.000526	CcSEcCtD
Epirubicin—Constipation—Vincristine—colon cancer	3.12e-05	0.000526	CcSEcCtD
Epirubicin—Asthma—Methotrexate—colon cancer	3.12e-05	0.000524	CcSEcCtD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—AKT1—colon cancer	3.12e-05	0.00129	CbGpPWpGaD
Epirubicin—Flushing—Capecitabine—colon cancer	3.11e-05	0.000523	CcSEcCtD
Epirubicin—Cardiac disorder—Capecitabine—colon cancer	3.11e-05	0.000523	CcSEcCtD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—AKT1—colon cancer	3.11e-05	0.00129	CbGpPWpGaD
Epirubicin—Musculoskeletal discomfort—Fluorouracil—colon cancer	3.11e-05	0.000522	CcSEcCtD
Epirubicin—Decreased appetite—Irinotecan—colon cancer	3.09e-05	0.00052	CcSEcCtD
Epirubicin—Eosinophilia—Methotrexate—colon cancer	3.09e-05	0.000519	CcSEcCtD
Epirubicin—Insomnia—Fluorouracil—colon cancer	3.08e-05	0.000518	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Irinotecan—colon cancer	3.07e-05	0.000517	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.07e-05	0.00127	CbGpPWpGaD
Epirubicin—Fatigue—Irinotecan—colon cancer	3.07e-05	0.000516	CcSEcCtD
Epirubicin—Paraesthesia—Fluorouracil—colon cancer	3.06e-05	0.000515	CcSEcCtD
Epirubicin—Pancreatitis—Methotrexate—colon cancer	3.06e-05	0.000514	CcSEcCtD
Epirubicin—ABCC1—Disease—LGR5—colon cancer	3.05e-05	0.00127	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CHST5—colon cancer	3.05e-05	0.00127	CbGpPWpGaD
Epirubicin—Constipation—Irinotecan—colon cancer	3.04e-05	0.000512	CcSEcCtD
Epirubicin—Pain—Irinotecan—colon cancer	3.04e-05	0.000512	CcSEcCtD
Epirubicin—Angiopathy—Capecitabine—colon cancer	3.04e-05	0.000512	CcSEcCtD
Epirubicin—Dyspnoea—Fluorouracil—colon cancer	3.04e-05	0.000511	CcSEcCtD
Epirubicin—PLA2G4A—Endothelins—AKT1—colon cancer	3.04e-05	0.00126	CbGpPWpGaD
Epirubicin—Somnolence—Fluorouracil—colon cancer	3.03e-05	0.00051	CcSEcCtD
Epirubicin—Immune system disorder—Capecitabine—colon cancer	3.03e-05	0.000509	CcSEcCtD
Epirubicin—Mediastinal disorder—Capecitabine—colon cancer	3.02e-05	0.000508	CcSEcCtD
Epirubicin—Chills—Capecitabine—colon cancer	3.01e-05	0.000506	CcSEcCtD
Epirubicin—Dyspepsia—Fluorouracil—colon cancer	3e-05	0.000505	CcSEcCtD
Epirubicin—Arrhythmia—Capecitabine—colon cancer	2.99e-05	0.000504	CcSEcCtD
Epirubicin—Gastrointestinal pain—Vincristine—colon cancer	2.99e-05	0.000503	CcSEcCtD
Epirubicin—Decreased appetite—Fluorouracil—colon cancer	2.96e-05	0.000498	CcSEcCtD
Epirubicin—Alopecia—Capecitabine—colon cancer	2.96e-05	0.000498	CcSEcCtD
Epirubicin—Pancytopenia—Methotrexate—colon cancer	2.96e-05	0.000498	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Fluorouracil—colon cancer	2.94e-05	0.000495	CcSEcCtD
Epirubicin—Mental disorder—Capecitabine—colon cancer	2.94e-05	0.000494	CcSEcCtD
Epirubicin—Feeling abnormal—Irinotecan—colon cancer	2.93e-05	0.000493	CcSEcCtD
Epirubicin—PLA2G4A—AGE/RAGE pathway—AKT1—colon cancer	2.93e-05	0.00121	CbGpPWpGaD
Epirubicin—Erythema—Capecitabine—colon cancer	2.92e-05	0.000491	CcSEcCtD
Epirubicin—Malnutrition—Capecitabine—colon cancer	2.92e-05	0.000491	CcSEcCtD
Epirubicin—Dysuria—Methotrexate—colon cancer	2.92e-05	0.00049	CcSEcCtD
Epirubicin—Neutropenia—Methotrexate—colon cancer	2.92e-05	0.00049	CcSEcCtD
Epirubicin—Pain—Fluorouracil—colon cancer	2.91e-05	0.00049	CcSEcCtD
Epirubicin—Gastrointestinal pain—Irinotecan—colon cancer	2.91e-05	0.000489	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—BUB1B—colon cancer	2.91e-05	0.00121	CbGpPWpGaD
Epirubicin—Upper respiratory tract infection—Methotrexate—colon cancer	2.9e-05	0.000487	CcSEcCtD
Epirubicin—Abdominal pain—Vincristine—colon cancer	2.89e-05	0.000486	CcSEcCtD
Epirubicin—Body temperature increased—Vincristine—colon cancer	2.89e-05	0.000486	CcSEcCtD
Epirubicin—YWHAG—Apoptosis—TP53—colon cancer	2.89e-05	0.0012	CbGpPWpGaD
Epirubicin—Flatulence—Capecitabine—colon cancer	2.88e-05	0.000484	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	2.87e-05	0.00119	CbGpPWpGaD
Epirubicin—Dysgeusia—Capecitabine—colon cancer	2.86e-05	0.000481	CcSEcCtD
Epirubicin—Photosensitivity reaction—Methotrexate—colon cancer	2.85e-05	0.000479	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—DLC1—colon cancer	2.84e-05	0.00118	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—SRC—colon cancer	2.82e-05	0.00117	CbGpPWpGaD
Epirubicin—Back pain—Capecitabine—colon cancer	2.82e-05	0.000475	CcSEcCtD
Epirubicin—Body temperature increased—Irinotecan—colon cancer	2.81e-05	0.000473	CcSEcCtD
Epirubicin—Abdominal pain—Irinotecan—colon cancer	2.81e-05	0.000473	CcSEcCtD
Epirubicin—Feeling abnormal—Fluorouracil—colon cancer	2.81e-05	0.000472	CcSEcCtD
Epirubicin—Muscle spasms—Capecitabine—colon cancer	2.81e-05	0.000472	CcSEcCtD
Epirubicin—Pneumonia—Methotrexate—colon cancer	2.8e-05	0.00047	CcSEcCtD
Epirubicin—Drowsiness—Methotrexate—colon cancer	2.78e-05	0.000468	CcSEcCtD
Epirubicin—Infestation NOS—Methotrexate—colon cancer	2.78e-05	0.000468	CcSEcCtD
Epirubicin—Infestation—Methotrexate—colon cancer	2.78e-05	0.000468	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Methotrexate—colon cancer	2.76e-05	0.000464	CcSEcCtD
Epirubicin—Vision blurred—Capecitabine—colon cancer	2.75e-05	0.000463	CcSEcCtD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—MYC—colon cancer	2.75e-05	0.00114	CbGpPWpGaD
Epirubicin—Renal failure—Methotrexate—colon cancer	2.73e-05	0.00046	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—NRAS—colon cancer	2.72e-05	0.00113	CbGpPWpGaD
Epirubicin—Stomatitis—Methotrexate—colon cancer	2.71e-05	0.000456	CcSEcCtD
Epirubicin—Ill-defined disorder—Capecitabine—colon cancer	2.71e-05	0.000455	CcSEcCtD
Epirubicin—Urticaria—Fluorouracil—colon cancer	2.71e-05	0.000455	CcSEcCtD
Epirubicin—Conjunctivitis—Methotrexate—colon cancer	2.7e-05	0.000454	CcSEcCtD
Epirubicin—Anaemia—Capecitabine—colon cancer	2.7e-05	0.000454	CcSEcCtD
Epirubicin—Body temperature increased—Fluorouracil—colon cancer	2.69e-05	0.000453	CcSEcCtD
Epirubicin—Hypersensitivity—Vincristine—colon cancer	2.69e-05	0.000453	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—LGR5—colon cancer	2.67e-05	0.00111	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	2.67e-05	0.00111	CbGpPWpGaD
Epirubicin—Sweating—Methotrexate—colon cancer	2.67e-05	0.000448	CcSEcCtD
Epirubicin—Haematuria—Methotrexate—colon cancer	2.65e-05	0.000446	CcSEcCtD
Epirubicin—Malaise—Capecitabine—colon cancer	2.63e-05	0.000443	CcSEcCtD
Epirubicin—Hepatobiliary disease—Methotrexate—colon cancer	2.63e-05	0.000442	CcSEcCtD
Epirubicin—Epistaxis—Methotrexate—colon cancer	2.62e-05	0.000441	CcSEcCtD
Epirubicin—Vertigo—Capecitabine—colon cancer	2.62e-05	0.000441	CcSEcCtD
Epirubicin—Hypersensitivity—Irinotecan—colon cancer	2.62e-05	0.000441	CcSEcCtD
Epirubicin—Asthenia—Vincristine—colon cancer	2.62e-05	0.000441	CcSEcCtD
Epirubicin—Syncope—Capecitabine—colon cancer	2.62e-05	0.00044	CcSEcCtD
Epirubicin—Leukopenia—Capecitabine—colon cancer	2.61e-05	0.000439	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	2.59e-05	0.00108	CbGpPWpGaD
Epirubicin—Agranulocytosis—Methotrexate—colon cancer	2.59e-05	0.000436	CcSEcCtD
Epirubicin—Palpitations—Capecitabine—colon cancer	2.58e-05	0.000434	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	2.57e-05	0.00107	CbGpPWpGaD
Epirubicin—Loss of consciousness—Capecitabine—colon cancer	2.56e-05	0.000431	CcSEcCtD
Epirubicin—ABCC1—Metabolism—CHST5—colon cancer	2.56e-05	0.00106	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ODC1—colon cancer	2.56e-05	0.00106	CbGpPWpGaD
Epirubicin—Asthenia—Irinotecan—colon cancer	2.55e-05	0.000429	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.55e-05	0.00106	CbGpPWpGaD
Epirubicin—Cough—Capecitabine—colon cancer	2.55e-05	0.000428	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—MYC—colon cancer	2.53e-05	0.00105	CbGpPWpGaD
Epirubicin—Hypertension—Capecitabine—colon cancer	2.52e-05	0.000424	CcSEcCtD
Epirubicin—Hypersensitivity—Fluorouracil—colon cancer	2.51e-05	0.000422	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	2.51e-05	0.00104	CbGpPWpGaD
Epirubicin—Haemoglobin—Methotrexate—colon cancer	2.51e-05	0.000422	CcSEcCtD
Epirubicin—Diarrhoea—Vincristine—colon cancer	2.5e-05	0.00042	CcSEcCtD
Epirubicin—DHCR7—Metabolism—ABCB1—colon cancer	2.5e-05	0.00104	CbGpPWpGaD
Epirubicin—Haemorrhage—Methotrexate—colon cancer	2.5e-05	0.00042	CcSEcCtD
Epirubicin—Hepatitis—Methotrexate—colon cancer	2.5e-05	0.00042	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—TYMS—colon cancer	2.49e-05	0.00103	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	2.49e-05	0.00103	CbGpPWpGaD
Epirubicin—Arthralgia—Capecitabine—colon cancer	2.48e-05	0.000418	CcSEcCtD
Epirubicin—Myalgia—Capecitabine—colon cancer	2.48e-05	0.000418	CcSEcCtD
Epirubicin—Chest pain—Capecitabine—colon cancer	2.48e-05	0.000418	CcSEcCtD
Epirubicin—Pharyngitis—Methotrexate—colon cancer	2.48e-05	0.000417	CcSEcCtD
Epirubicin—Anxiety—Capecitabine—colon cancer	2.48e-05	0.000416	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	2.47e-05	0.000415	CcSEcCtD
Epirubicin—Urinary tract disorder—Methotrexate—colon cancer	2.46e-05	0.000414	CcSEcCtD
Epirubicin—Discomfort—Capecitabine—colon cancer	2.45e-05	0.000413	CcSEcCtD
Epirubicin—DHCR7—Metabolism—TYMS—colon cancer	2.45e-05	0.00102	CbGpPWpGaD
Epirubicin—Urethral disorder—Methotrexate—colon cancer	2.45e-05	0.000411	CcSEcCtD
Epirubicin—YWHAG—Apoptosis—AKT1—colon cancer	2.44e-05	0.00101	CbGpPWpGaD
Epirubicin—Diarrhoea—Irinotecan—colon cancer	2.43e-05	0.000409	CcSEcCtD
Epirubicin—Dry mouth—Capecitabine—colon cancer	2.43e-05	0.000409	CcSEcCtD
Epirubicin—Dizziness—Vincristine—colon cancer	2.42e-05	0.000406	CcSEcCtD
Epirubicin—Pruritus—Fluorouracil—colon cancer	2.41e-05	0.000406	CcSEcCtD
Epirubicin—Visual impairment—Methotrexate—colon cancer	2.4e-05	0.000404	CcSEcCtD
Epirubicin—Confusional state—Capecitabine—colon cancer	2.4e-05	0.000404	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	2.39e-05	0.00099	CbGpPWpGaD
Epirubicin—Oedema—Capecitabine—colon cancer	2.38e-05	0.000401	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—CCND1—colon cancer	2.37e-05	0.000982	CbGpPWpGaD
Epirubicin—Infection—Capecitabine—colon cancer	2.37e-05	0.000398	CcSEcCtD
Epirubicin—Erythema multiforme—Methotrexate—colon cancer	2.36e-05	0.000397	CcSEcCtD
Epirubicin—Dizziness—Irinotecan—colon cancer	2.35e-05	0.000396	CcSEcCtD
Epirubicin—Shock—Capecitabine—colon cancer	2.34e-05	0.000394	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—KRAS—colon cancer	2.34e-05	0.00097	CbGpPWpGaD
Epirubicin—Nervous system disorder—Capecitabine—colon cancer	2.34e-05	0.000393	CcSEcCtD
Epirubicin—Eye disorder—Methotrexate—colon cancer	2.33e-05	0.000392	CcSEcCtD
Epirubicin—Diarrhoea—Fluorouracil—colon cancer	2.33e-05	0.000392	CcSEcCtD
Epirubicin—Thrombocytopenia—Capecitabine—colon cancer	2.33e-05	0.000392	CcSEcCtD
Epirubicin—Tinnitus—Methotrexate—colon cancer	2.33e-05	0.000391	CcSEcCtD
Epirubicin—Tachycardia—Capecitabine—colon cancer	2.32e-05	0.000391	CcSEcCtD
Epirubicin—Vomiting—Vincristine—colon cancer	2.32e-05	0.000391	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	2.32e-05	0.000963	CbGpPWpGaD
Epirubicin—Cardiac disorder—Methotrexate—colon cancer	2.32e-05	0.00039	CcSEcCtD
Epirubicin—Skin disorder—Capecitabine—colon cancer	2.31e-05	0.000389	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	2.31e-05	0.000957	CbGpPWpGaD
Epirubicin—Rash—Vincristine—colon cancer	2.3e-05	0.000387	CcSEcCtD
Epirubicin—Hyperhidrosis—Capecitabine—colon cancer	2.3e-05	0.000387	CcSEcCtD
Epirubicin—Dermatitis—Vincristine—colon cancer	2.3e-05	0.000387	CcSEcCtD
Epirubicin—TOP2A—Circadian rythm related genes—EP300—colon cancer	2.29e-05	0.000951	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—CDKN1A—colon cancer	2.29e-05	0.00095	CbGpPWpGaD
Epirubicin—Headache—Vincristine—colon cancer	2.29e-05	0.000385	CcSEcCtD
Epirubicin—UGT2B7—NRF2 pathway—TGFB1—colon cancer	2.27e-05	0.000943	CbGpPWpGaD
Epirubicin—Anorexia—Capecitabine—colon cancer	2.27e-05	0.000382	CcSEcCtD
Epirubicin—Angiopathy—Methotrexate—colon cancer	2.26e-05	0.000381	CcSEcCtD
Epirubicin—Vomiting—Irinotecan—colon cancer	2.26e-05	0.000381	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	2.26e-05	0.000938	CbGpPWpGaD
Epirubicin—Immune system disorder—Methotrexate—colon cancer	2.25e-05	0.000379	CcSEcCtD
Epirubicin—Dizziness—Fluorouracil—colon cancer	2.25e-05	0.000379	CcSEcCtD
Epirubicin—Mediastinal disorder—Methotrexate—colon cancer	2.25e-05	0.000378	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	2.25e-05	0.000932	CbGpPWpGaD
Epirubicin—Rash—Irinotecan—colon cancer	2.24e-05	0.000377	CcSEcCtD
Epirubicin—Dermatitis—Irinotecan—colon cancer	2.24e-05	0.000377	CcSEcCtD
Epirubicin—Chills—Methotrexate—colon cancer	2.24e-05	0.000377	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—TYMS—colon cancer	2.23e-05	0.000925	CbGpPWpGaD
Epirubicin—Headache—Irinotecan—colon cancer	2.23e-05	0.000375	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	2.23e-05	0.000923	CbGpPWpGaD
Epirubicin—Hypotension—Capecitabine—colon cancer	2.23e-05	0.000374	CcSEcCtD
Epirubicin—Alopecia—Methotrexate—colon cancer	2.21e-05	0.000371	CcSEcCtD
Epirubicin—ABCC1—Disease—AXIN2—colon cancer	2.19e-05	0.000909	CbGpPWpGaD
Epirubicin—Mental disorder—Methotrexate—colon cancer	2.19e-05	0.000368	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—EP300—colon cancer	2.18e-05	0.000904	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	2.17e-05	0.000901	CbGpPWpGaD
Epirubicin—Erythema—Methotrexate—colon cancer	2.17e-05	0.000365	CcSEcCtD
Epirubicin—Malnutrition—Methotrexate—colon cancer	2.17e-05	0.000365	CcSEcCtD
Epirubicin—Nausea—Vincristine—colon cancer	2.17e-05	0.000365	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Capecitabine—colon cancer	2.17e-05	0.000365	CcSEcCtD
Epirubicin—Vomiting—Fluorouracil—colon cancer	2.17e-05	0.000364	CcSEcCtD
Epirubicin—Insomnia—Capecitabine—colon cancer	2.15e-05	0.000362	CcSEcCtD
Epirubicin—Rash—Fluorouracil—colon cancer	2.15e-05	0.000361	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—PIK3CA—colon cancer	2.15e-05	0.000891	CbGpPWpGaD
Epirubicin—Dermatitis—Fluorouracil—colon cancer	2.15e-05	0.000361	CcSEcCtD
Epirubicin—Paraesthesia—Capecitabine—colon cancer	2.14e-05	0.00036	CcSEcCtD
Epirubicin—Headache—Fluorouracil—colon cancer	2.14e-05	0.000359	CcSEcCtD
Epirubicin—Dysgeusia—Methotrexate—colon cancer	2.13e-05	0.000358	CcSEcCtD
Epirubicin—Dyspnoea—Capecitabine—colon cancer	2.12e-05	0.000357	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—CCND1—colon cancer	2.12e-05	0.000878	CbGpPWpGaD
Epirubicin—Nausea—Irinotecan—colon cancer	2.11e-05	0.000355	CcSEcCtD
Epirubicin—Back pain—Methotrexate—colon cancer	2.1e-05	0.000353	CcSEcCtD
Epirubicin—Dyspepsia—Capecitabine—colon cancer	2.1e-05	0.000353	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	2.08e-05	0.000863	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	2.08e-05	0.000861	CbGpPWpGaD
Epirubicin—YWHAG—Membrane Trafficking—AKT1—colon cancer	2.07e-05	0.000859	CbGpPWpGaD
Epirubicin—Decreased appetite—Capecitabine—colon cancer	2.07e-05	0.000348	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	2.07e-05	0.000858	CbGpPWpGaD
Epirubicin—Gastrointestinal disorder—Capecitabine—colon cancer	2.06e-05	0.000346	CcSEcCtD
Epirubicin—Fatigue—Capecitabine—colon cancer	2.05e-05	0.000345	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—CDKN1A—colon cancer	2.05e-05	0.00085	CbGpPWpGaD
Epirubicin—Vision blurred—Methotrexate—colon cancer	2.05e-05	0.000344	CcSEcCtD
Epirubicin—Constipation—Capecitabine—colon cancer	2.04e-05	0.000343	CcSEcCtD
Epirubicin—Pain—Capecitabine—colon cancer	2.04e-05	0.000343	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	2.04e-05	0.000844	CbGpPWpGaD
Epirubicin—Nausea—Fluorouracil—colon cancer	2.02e-05	0.00034	CcSEcCtD
Epirubicin—Ill-defined disorder—Methotrexate—colon cancer	2.02e-05	0.000339	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	2.01e-05	0.000834	CbGpPWpGaD
Epirubicin—Anaemia—Methotrexate—colon cancer	2.01e-05	0.000338	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—HRAS—colon cancer	1.99e-05	0.000824	CbGpPWpGaD
Epirubicin—PLA2G4A—Phospholipid metabolism—PIK3CA—colon cancer	1.98e-05	0.000823	CbGpPWpGaD
Epirubicin—Feeling abnormal—Capecitabine—colon cancer	1.96e-05	0.00033	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.96e-05	0.000812	CbGpPWpGaD
Epirubicin—Malaise—Methotrexate—colon cancer	1.96e-05	0.000329	CcSEcCtD
Epirubicin—Vertigo—Methotrexate—colon cancer	1.95e-05	0.000328	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—EP300—colon cancer	1.95e-05	0.000809	CbGpPWpGaD
Epirubicin—Gastrointestinal pain—Capecitabine—colon cancer	1.95e-05	0.000328	CcSEcCtD
Epirubicin—Leukopenia—Methotrexate—colon cancer	1.94e-05	0.000327	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.92e-05	0.000797	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AXIN2—colon cancer	1.92e-05	0.000797	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—MYC—colon cancer	1.9e-05	0.000788	CbGpPWpGaD
Epirubicin—Cough—Methotrexate—colon cancer	1.9e-05	0.000319	CcSEcCtD
Epirubicin—Urticaria—Capecitabine—colon cancer	1.89e-05	0.000318	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.89e-05	0.000783	CbGpPWpGaD
Epirubicin—Abdominal pain—Capecitabine—colon cancer	1.88e-05	0.000317	CcSEcCtD
Epirubicin—Body temperature increased—Capecitabine—colon cancer	1.88e-05	0.000317	CcSEcCtD
Epirubicin—Convulsion—Methotrexate—colon cancer	1.88e-05	0.000317	CcSEcCtD
Epirubicin—Chest pain—Methotrexate—colon cancer	1.85e-05	0.000311	CcSEcCtD
Epirubicin—Arthralgia—Methotrexate—colon cancer	1.85e-05	0.000311	CcSEcCtD
Epirubicin—Myalgia—Methotrexate—colon cancer	1.85e-05	0.000311	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	1.84e-05	0.000309	CcSEcCtD
Epirubicin—Discomfort—Methotrexate—colon cancer	1.83e-05	0.000307	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.8e-05	0.000747	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.8e-05	0.000746	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CCND1—colon cancer	1.8e-05	0.000745	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—SRC—colon cancer	1.79e-05	0.000742	CbGpPWpGaD
Epirubicin—Confusional state—Methotrexate—colon cancer	1.79e-05	0.000301	CcSEcCtD
Epirubicin—Anaphylactic shock—Methotrexate—colon cancer	1.77e-05	0.000298	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.77e-05	0.000732	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.76e-05	0.000731	CbGpPWpGaD
Epirubicin—Infection—Methotrexate—colon cancer	1.76e-05	0.000296	CcSEcCtD
Epirubicin—Hypersensitivity—Capecitabine—colon cancer	1.75e-05	0.000295	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—colon cancer	1.74e-05	0.000723	CbGpPWpGaD
Epirubicin—Nervous system disorder—Methotrexate—colon cancer	1.74e-05	0.000292	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CDKN1A—colon cancer	1.74e-05	0.00072	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PPARG—colon cancer	1.74e-05	0.00072	CbGpPWpGaD
Epirubicin—Thrombocytopenia—Methotrexate—colon cancer	1.74e-05	0.000292	CcSEcCtD
Epirubicin—Skin disorder—Methotrexate—colon cancer	1.72e-05	0.00029	CcSEcCtD
Epirubicin—Hyperhidrosis—Methotrexate—colon cancer	1.71e-05	0.000288	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.71e-05	0.000709	CbGpPWpGaD
Epirubicin—Asthenia—Capecitabine—colon cancer	1.71e-05	0.000287	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—MYC—colon cancer	1.7e-05	0.000705	CbGpPWpGaD
Epirubicin—Anorexia—Methotrexate—colon cancer	1.69e-05	0.000284	CcSEcCtD
Epirubicin—Pruritus—Capecitabine—colon cancer	1.69e-05	0.000283	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.67e-05	0.000691	CbGpPWpGaD
Epirubicin—Hypotension—Methotrexate—colon cancer	1.66e-05	0.000279	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—EP300—colon cancer	1.65e-05	0.000685	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—TP53—colon cancer	1.64e-05	0.00068	CbGpPWpGaD
Epirubicin—Diarrhoea—Capecitabine—colon cancer	1.63e-05	0.000274	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Methotrexate—colon cancer	1.62e-05	0.000272	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—CCND1—colon cancer	1.61e-05	0.000666	CbGpPWpGaD
Epirubicin—Insomnia—Methotrexate—colon cancer	1.6e-05	0.00027	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—colon cancer	1.6e-05	0.000663	CbGpPWpGaD
Epirubicin—Paraesthesia—Methotrexate—colon cancer	1.59e-05	0.000268	CcSEcCtD
Epirubicin—Dyspnoea—Methotrexate—colon cancer	1.58e-05	0.000266	CcSEcCtD
Epirubicin—Somnolence—Methotrexate—colon cancer	1.58e-05	0.000265	CcSEcCtD
Epirubicin—Dizziness—Capecitabine—colon cancer	1.57e-05	0.000265	CcSEcCtD
Epirubicin—Dyspepsia—Methotrexate—colon cancer	1.56e-05	0.000262	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—CDKN1A—colon cancer	1.55e-05	0.000644	CbGpPWpGaD
Epirubicin—Decreased appetite—Methotrexate—colon cancer	1.54e-05	0.000259	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Methotrexate—colon cancer	1.53e-05	0.000257	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.53e-05	0.000635	CbGpPWpGaD
Epirubicin—Fatigue—Methotrexate—colon cancer	1.53e-05	0.000257	CcSEcCtD
Epirubicin—Pain—Methotrexate—colon cancer	1.52e-05	0.000255	CcSEcCtD
Epirubicin—Vomiting—Capecitabine—colon cancer	1.51e-05	0.000255	CcSEcCtD
Epirubicin—Rash—Capecitabine—colon cancer	1.5e-05	0.000253	CcSEcCtD
Epirubicin—Dermatitis—Capecitabine—colon cancer	1.5e-05	0.000252	CcSEcCtD
Epirubicin—Headache—Capecitabine—colon cancer	1.49e-05	0.000251	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.48e-05	0.000614	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—EP300—colon cancer	1.48e-05	0.000613	CbGpPWpGaD
Epirubicin—Feeling abnormal—Methotrexate—colon cancer	1.46e-05	0.000246	CcSEcCtD
Epirubicin—Gastrointestinal pain—Methotrexate—colon cancer	1.45e-05	0.000244	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.44e-05	0.000598	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—ABCB1—colon cancer	1.44e-05	0.000598	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—MYC—colon cancer	1.44e-05	0.000597	CbGpPWpGaD
Epirubicin—Nausea—Capecitabine—colon cancer	1.41e-05	0.000238	CcSEcCtD
Epirubicin—Urticaria—Methotrexate—colon cancer	1.41e-05	0.000237	CcSEcCtD
Epirubicin—Abdominal pain—Methotrexate—colon cancer	1.4e-05	0.000236	CcSEcCtD
Epirubicin—Body temperature increased—Methotrexate—colon cancer	1.4e-05	0.000236	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—TP53—colon cancer	1.4e-05	0.000579	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PTGS2—colon cancer	1.37e-05	0.000567	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	1.36e-05	0.000565	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.32e-05	0.000547	CbGpPWpGaD
Epirubicin—Hypersensitivity—Methotrexate—colon cancer	1.31e-05	0.00022	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—MYC—colon cancer	1.29e-05	0.000534	CbGpPWpGaD
Epirubicin—Asthenia—Methotrexate—colon cancer	1.27e-05	0.000214	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CCND1—colon cancer	1.26e-05	0.000521	CbGpPWpGaD
Epirubicin—Pruritus—Methotrexate—colon cancer	1.25e-05	0.000211	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.25e-05	0.000518	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDKN1A—colon cancer	1.22e-05	0.000504	CbGpPWpGaD
Epirubicin—Diarrhoea—Methotrexate—colon cancer	1.21e-05	0.000204	CcSEcCtD
Epirubicin—Dizziness—Methotrexate—colon cancer	1.17e-05	0.000197	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—EP300—colon cancer	1.16e-05	0.000479	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—EP300—colon cancer	1.14e-05	0.000471	CbGpPWpGaD
Epirubicin—Vomiting—Methotrexate—colon cancer	1.13e-05	0.00019	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CCND1—colon cancer	1.12e-05	0.000466	CbGpPWpGaD
Epirubicin—Rash—Methotrexate—colon cancer	1.12e-05	0.000188	CcSEcCtD
Epirubicin—Dermatitis—Methotrexate—colon cancer	1.12e-05	0.000188	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—colon cancer	1.11e-05	0.000461	CbGpPWpGaD
Epirubicin—Headache—Methotrexate—colon cancer	1.11e-05	0.000187	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CDKN1A—colon cancer	1.09e-05	0.00045	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—colon cancer	1.06e-05	0.000439	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.05e-05	0.000437	CbGpPWpGaD
Epirubicin—Nausea—Methotrexate—colon cancer	1.05e-05	0.000177	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.04e-05	0.000431	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—EP300—colon cancer	1.03e-05	0.000429	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MYC—colon cancer	1.01e-05	0.000418	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—EP300—colon cancer	9.49e-06	0.000393	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—SRC—colon cancer	9.23e-06	0.000383	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MYC—colon cancer	9.01e-06	0.000373	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—VEGFA—colon cancer	8.99e-06	0.000373	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—NRAS—colon cancer	8.88e-06	0.000368	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—colon cancer	8.64e-06	0.000358	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ABCB1—colon cancer	8.62e-06	0.000357	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—TYMS—colon cancer	8.46e-06	0.000351	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ABCB1—colon cancer	8.45e-06	0.00035	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PIK3CA—colon cancer	8.41e-06	0.000349	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—TYMS—colon cancer	8.3e-06	0.000344	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	8.3e-06	0.000344	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TGFB1—colon cancer	8.25e-06	0.000342	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—KRAS—colon cancer	7.64e-06	0.000317	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TP53—colon cancer	7.4e-06	0.000307	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—PIK3CA—colon cancer	7.02e-06	0.000291	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—EP300—colon cancer	6.9e-06	0.000286	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—AKT1—colon cancer	6.87e-06	0.000285	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TP53—colon cancer	6.79e-06	0.000282	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ABCB1—colon cancer	6.75e-06	0.00028	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—TYMS—colon cancer	6.63e-06	0.000275	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—HRAS—colon cancer	6.49e-06	0.000269	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	6.39e-06	0.000265	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FGFR3—colon cancer	6.33e-06	0.000263	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PPARG—colon cancer	6e-06	0.000249	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PPARG—colon cancer	5.88e-06	0.000244	CbGpPWpGaD
Epirubicin—ABCC1—Disease—APC—colon cancer	5.81e-06	0.000241	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—AKT1—colon cancer	5.73e-06	0.000238	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FGFR3—colon cancer	5.55e-06	0.00023	CbGpPWpGaD
Epirubicin—ABCC1—Disease—BRAF—colon cancer	5.46e-06	0.000227	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.11e-06	0.000212	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—APC—colon cancer	5.09e-06	0.000211	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—NRAS—colon cancer	5.09e-06	0.000211	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—BRAF—colon cancer	4.79e-06	0.000199	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTGS2—colon cancer	4.72e-06	0.000196	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PPARG—colon cancer	4.7e-06	0.000195	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—EGFR—colon cancer	4.64e-06	0.000192	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTGS2—colon cancer	4.63e-06	0.000192	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTGS2—colon cancer	4.41e-06	0.000183	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—KRAS—colon cancer	4.38e-06	0.000182	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CA—colon cancer	4.03e-06	0.000167	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CTNNB1—colon cancer	3.95e-06	0.000164	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—EP300—colon cancer	3.92e-06	0.000163	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CDKN1A—colon cancer	3.86e-06	0.00016	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—EP300—colon cancer	3.85e-06	0.00016	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—HRAS—colon cancer	3.73e-06	0.000155	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTGS2—colon cancer	3.7e-06	0.000153	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EP300—colon cancer	3.67e-06	0.000152	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CASP3—colon cancer	3.59e-06	0.000149	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SRC—colon cancer	3.57e-06	0.000148	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCND1—colon cancer	3.49e-06	0.000145	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CTNNB1—colon cancer	3.46e-06	0.000143	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NRAS—colon cancer	3.43e-06	0.000142	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CDKN1A—colon cancer	3.38e-06	0.00014	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—AKT1—colon cancer	3.29e-06	0.000136	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EP300—colon cancer	3.22e-06	0.000133	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MYC—colon cancer	3.2e-06	0.000133	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TGFB1—colon cancer	3.19e-06	0.000132	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGFR—colon cancer	3.13e-06	0.00013	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SRC—colon cancer	3.13e-06	0.00013	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—EP300—colon cancer	3.07e-06	0.000127	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFA—colon cancer	3.05e-06	0.000126	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NRAS—colon cancer	3.01e-06	0.000125	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KRAS—colon cancer	2.96e-06	0.000123	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CA—colon cancer	2.9e-06	0.00012	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CA—colon cancer	2.85e-06	0.000118	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MYC—colon cancer	2.8e-06	0.000116	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TGFB1—colon cancer	2.8e-06	0.000116	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGFR—colon cancer	2.74e-06	0.000114	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CA—colon cancer	2.72e-06	0.000113	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KRAS—colon cancer	2.59e-06	0.000107	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HRAS—colon cancer	2.51e-06	0.000104	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CA—colon cancer	2.38e-06	9.87e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—AKT1—colon cancer	2.37e-06	9.83e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—AKT1—colon cancer	2.32e-06	9.64e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—colon cancer	2.3e-06	9.55e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CA—colon cancer	2.27e-06	9.43e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—AKT1—colon cancer	2.22e-06	9.2e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HRAS—colon cancer	2.2e-06	9.13e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AKT1—colon cancer	1.94e-06	8.06e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—AKT1—colon cancer	1.86e-06	7.7e-05	CbGpPWpGaD
